Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1120185.RAkb2pt4NZAl3e7rRzRjMApE7_avvsb1EacDyEs0qR7P4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1120185.RAkb2pt4NZAl3e7rRzRjMApE7_avvsb1EacDyEs0qR7P4130_assertion type Assertion NP1120185.RAkb2pt4NZAl3e7rRzRjMApE7_avvsb1EacDyEs0qR7P4130_head.
- NP1120185.RAkb2pt4NZAl3e7rRzRjMApE7_avvsb1EacDyEs0qR7P4130_assertion description "[In non-small-cell lung cancer (NSCLC), the identification of oncogenic driver mutations led to the definition of different clinical entities with different therapeutic opportunities, as demonstrated in patients harboring EGF receptor (EGFR) mutations or anaplastic lymphoma kinase translocations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1120185.RAkb2pt4NZAl3e7rRzRjMApE7_avvsb1EacDyEs0qR7P4130_provenance.
- NP1120185.RAkb2pt4NZAl3e7rRzRjMApE7_avvsb1EacDyEs0qR7P4130_assertion evidence source_evidence_literature NP1120185.RAkb2pt4NZAl3e7rRzRjMApE7_avvsb1EacDyEs0qR7P4130_provenance.
- NP1120185.RAkb2pt4NZAl3e7rRzRjMApE7_avvsb1EacDyEs0qR7P4130_assertion SIO_000772 24134423 NP1120185.RAkb2pt4NZAl3e7rRzRjMApE7_avvsb1EacDyEs0qR7P4130_provenance.
- NP1120185.RAkb2pt4NZAl3e7rRzRjMApE7_avvsb1EacDyEs0qR7P4130_assertion wasDerivedFrom befree-2016 NP1120185.RAkb2pt4NZAl3e7rRzRjMApE7_avvsb1EacDyEs0qR7P4130_provenance.
- NP1120185.RAkb2pt4NZAl3e7rRzRjMApE7_avvsb1EacDyEs0qR7P4130_assertion wasGeneratedBy ECO_0000203 NP1120185.RAkb2pt4NZAl3e7rRzRjMApE7_avvsb1EacDyEs0qR7P4130_provenance.